REGENERON PHARMACEUTICALS, INC. Proceeds from Convertible Debt
REGENERON PHARMACEUTICALS, INC. (REGN) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2014-02-13
- REGENERON PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2013 was $0.00.
- REGENERON PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- REGENERON PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2011 was $391.11M.
| Period end | Proceeds from Convertible Debt 12 month |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-13 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-13 |
| 2011-12-31 | $391.11M 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |